Insight

Psychedelic drugs: A market poised for takeoff

With success in clinical trials for a range of mental disorders, psychedelics may soon move to the medical mainstream.

Psychedelic drugs are showing efficacy in clinical trials for a range of conditions, from post-traumatic stress disorder to depression. With the market expected to grow to $6.8 billion by 2027, psychedelics are attracting the attention of large biopharma companies looking to get in on a new growth area. For example, the drug MDMA, in 2021 was shown to have significant benefits in the treatment of PTSD when used in combination with in-patient therapy. As these drugs move from the medical fringes to the mainstream, they have attracted $1.8 billion in venture capital investment. Most big pharma companies have remained on the sidelines until regulators give their approval for a variety of treatments.

If you are interested in the future market for psychedelic drugs for medical purposes, this paper is a chance to find out which companies have taken the forefront in development.

Contact us

Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 732-429-9612
Jeff Stoll, PhD

Jeff Stoll, PhD

Principal, National Strategy Life Sciences Leader, KPMG US

+1 857-334-8768

Related content


KPMG Healthcare & Life Sciences Institute

Register to receive timely insights

Register to receive timely insights

About Healthcare & Life Sciences at KPMG

Our practice

Learn more


Our capabilities

Learn more


Meet our team

Learn more